AXIS 1 "RESEARCH, TECHNOLOGICAL DEVELOPMENT AND INNOVATION ACTION 1.1.4 “Support for collaborative R&D activities for the development of new sustainable technologies, products and services”
PRELIMINARY EFFICACY STUDY OF A FOOD SUPPLEMENT TO SUPPORT NCGS (Non-celiac gluten sensitivity) AND COELIAC DISEASE
Design and manufacture of a food supplement containing a plant enzyme and a probiotic. Study of the plant enzyme's proteolytic activity against gluten and the anti-inflammatory activity of the combination of active ingredients. Development of the finished product to improve its stability in terms of the viability of the probiotic strain.
Intervention realised with funding POR FESR 2014-2020 (Objective: '"Increasing business innovation activity").
Intervention carried out with the benefit of a grant from Regione Veneto amounting to euro 79.150.
PRODUCTION AND CHARACTERISATION OF AN AMARANTH EXTRACT FOR CARDIOVASCULAR HEALTH
Investigation and development of a food alternative with a health-promoting effect on the cardiovascular system. Field and vertical cultivations of different varieties of Amaranthus caudatus, production and characterisation of fluid extracts and simultaneous evaluation of biological activity.
Intervention realised with funding POR FESR 2014-2020 (Objective: "Increasing business innovation activity").
Intervention carried out with the benefit of a grant from Regione Veneto amounting to euro 35.375.
Thanks to the Regione Veneto and the European Union, Labomar has obtained important funding for the development of botanical extracts and food supplements to support health.
The precise study of products and the acquisition of new skills will enable Labomar to make important improvements in the production, proposition and positioning of its products.
Our focus is always on improving the entire production chain, services and the continuous raising of our quality standards, so that we can also address the most important international brands.
“Certified B Corporation” is a trademark licensed by B Lab, a private non-profit organization, to companies like ours that have successfully completed the B Impact Assessment (“BIA”) and therefore meet the requirements set by B Lab for social and environmental performance, accountability, and transparency. It is specified that B Lab is not a conformity assessment body as defined by Regulation (EU) No 765/2008, nor is it a national, European, or international standardization body as per Regulation (EU) No 1025/2012. The criteria of the BIA are distinct and independent from the harmonized standards resulting from ISO norms or other standardization bodies, and they are not ratified by national or European public institutions.
Financial Calendar
19 October 20233Q 2023 Consolidated Revenues Labomar Group
28 September 2023Board of Directors’ meeting to approve the Consolidated half-year report as at 30 June, 2023
20 July 20231H 2023 Consolidated Revenues Labomar Group
04 May 2023Second call for the Shareholders’ Meeting to approve the Separate Financial Statements of the Company and present the Consolidated Statements of the Group for the year ended December 31, 2022
28 April 2023First call for the Shareholders’ Meeting to approve the Separate Financial Statements of the Company and present the Consolidated Statements of the Group for the year ended December 31, 2022
20 April 20231Q 2023 Consolidated Revenues Labomar Group
29 March 2023Conference call with the financial market for the presentation of the Group's Consolidated Results for the year ended at December 31, 2022
29 March 2023Board of Directors’ meeting to approve the separate Financial Statements of the Company and the Consolidated Statements of the Group for the year ended December 31, 2022
26 January 20232022 Consolidated Revenues Labomar Group
18 October 20223Q 2022 Consolidated Revenues Labomar Group
27 September 2022Conference call with the financial market for the presentation of the Group’s Consolidated data as at 30 June 2022 (at 3.30 p.m. CET) - Link: https://services.choruscall.it/DiamondPassRegistration/register?confirmationNumber=5855752&linkSecurityString=644d70bb0
27 September 2022Board of Directors’ meeting to approve the Consolidated half-year report as at 30 June, 2022
19 July 20221H 2022 Consolidated Revenues Labomar Group
04 May 2022Second call for the Shareholders’ Meeting to approve the Separate Financial Statements of the Company and present the Consolidated Statements of the Group for the year ended December 31, 2021
27 April 2022First call for the Shareholders’ Meeting to approve the Separate Financial Statements of the Company and present the Consolidated Statements of the Group for the year ended December 31, 2021
20 April 20221Q 2022 Consolidated Revenues Labomar Group
28 March 2022Conference call with the financial market for the presentation of the Group’s Consolidated data as at 31 December 2021 (at 4.30 p.m. CET) - Link: https://services.choruscall.it/DiamondPassRegistration/register?confirmationNumber=5855752&linkSecurityString=644d70bb0
28 March 2022Board of Directors’ meeting to approve the separate Financial Statements of the Company and the Consolidated Statements of the Group for the year ended December 31, 2021
18 January 20222021 Consolidated Revenues Labomar Group
29 November 2021Partecipation to Mid&Small in Milan 2021
18 October 2021Investor Days
17 October 2021Investor Days
25 September 2021Board of Directors’ meeting to approve the consolidated half-year report as at 30 June 2021 - voluntarily submitted to audit. Conference call with financial market
29 August 20211H 2021 Financial results
24 July 2021Partecipation to Mid&Small Virtual Summer Conference
29 June 2021Partecipation to Italian Sustainability Week 2021 by Borsa Italiana
28 June 2021Partecipation to Italian Sustainability Week 2021 by Borsa Italiana
27 June 2021Partecipation to Italian Sustainability Week 2021 by Borsa Italiana
24 May 2021Partecipation to AIM Italian Conference organized by Borsa Italiana
16 May 2021Partecipation in the Equity Forum Spring Conference
01 May 2021Second call for the shareholders’ meeting to approve the separate financial statements of the Company and present the consolidated statements of the group for the year ended December 31, 2020
26 April 2021First call for the shareholders’ meeting to approve the separate financial statements of the Company and present the consolidated statements of the group for the year ended December 31, 2020
28 March 2021Financial market conference call to present consolidated figures for the Group for the year ended December 31, 2020
27 March 2021Board of Directors’ meeting to approve the separate financial statements of the Company and the consolidated statements of the group for the year ended December 31, 2020
